

# STATE OF NEW YORK

8243

2025-2026 Regular Sessions

## IN ASSEMBLY

May 5, 2025

Introduced by M. of A. PAULIN -- read once and referred to the Committee on Health

AN ACT to amend the public health law, in relation to establishing a state frontotemporal degeneration advisory committee

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

1 Section 1. The public health law is amended by adding a new article  
2 20-C to read as follows:

### ARTICLE 20-C

#### FRONTOTEMPORAL DEGENERATION ADVISORY COMMITTEE

5 Section 2020. Frontotemporal degeneration advisory committee.

#### 2021. Reports.

7 § 2020. Frontotemporal degeneration advisory committee. 1. The  
8 department shall, within ninety days of the effective date of this  
9 section, establish a frontotemporal degeneration advisory committee  
10 which shall be charged with recommending to the department long range  
11 objectives, goals and priorities. It shall also provide advice on the  
12 planning, coordination and development of needed services. In making  
13 such recommendations, the committee shall review and consider:

14 (a) rates of clinical diagnosis of frontotemporal degeneration by  
15 county;

16 (b) how many records have been included and reported into the depart-  
17 ment's frontotemporal degeneration registry;

18 (c) demographic information such as patients by age, gender and race;

19 (d) the number of new diagnoses in the preceding year;

20 (e) advancements in the treatment of frontotemporal degeneration;

21 (f) the availability and accessibility of resources for the care of  
22 patients with frontotemporal degeneration and any disparities that may  
23 exist in the regional availability of services;

24 (g) information related to the cost of care for frontotemporal degen-  
25 eration disorders; and

EXPLANATION--Matter in italics (underscored) is new; matter in brackets  
[-] is old law to be omitted.

LBD11679-01-5

1 (h) frequency of and causes of misdiagnosis related to frontotemporal  
2 degeneration disorders.

3 2. Members of the committee shall be selected by the governor, the  
4 legislature and the commissioner. The governor, the temporary president  
5 of the senate, the speaker of the assembly and the commissioner shall  
6 each select two committee members and the minority leaders of the senate  
7 and the assembly shall each select one committee member. Membership of  
8 the committee shall include:

9 (i) a neurologist;

10 (ii) a speech pathologist;

11 (iii) a primary care provider;

12 (iv) a physician informaticist;

13 (v) a patient living with frontotemporal degeneration;

14 (vi) a caregiver of a patient living with frontotemporal degeneration;

15 (vii) a public health professional;

16 (viii) a population health researcher familiar with registries;

17 (ix) a frontotemporal degeneration researcher;

18 (x) a member of an organization that raises awareness about and  
19 promotes research for the treatment of frontotemporal degeneration; and

20 (xi) anyone else the commissioner deems necessary.

21 3. The members of the committee shall receive no compensation for  
22 their services, but shall be allowed their actual and necessary expenses  
23 incurred in the performance of their duties hereunder, subject to the  
24 approval of the commissioner.

25 § 2021. Reports. 1. On or before January first, two thousand twenty-  
26 seven, and every year thereafter, the department, in conjunction with  
27 the advisory committee, shall report to the legislature and governor a  
28 yearly program summary update on the rate of clinical diagnoses of fron-  
29 totemporal degeneration disorders in the state. Such report shall  
30 include:

31 (a) the incidence and prevalence of frontotemporal degeneration by  
32 county;

33 (b) how many records have been included and reported into the regis-  
34 try;

35 (c) demographic information such as patients by age, gender and race;

36 (d) the number of new diagnoses in the preceding year;

37 (e) a summary of advancements in the treatment and newly developed  
38 treatments of frontotemporal degeneration;

39 (f) a list of resources for the families of patients diagnosed with  
40 frontotemporal degeneration disorder, which shall include but not be  
41 limited to support from the state or federal government, support groups  
42 and helplines;

43 (g) the resources available for the care of patients with frontotempo-  
44 ral degeneration by region;

45 (h) information related to the cost of care for patients who have been  
46 diagnosed with frontotemporal degeneration disorder; and

47 (i) the number of patients diagnosed with frontotemporal degeneration  
48 disorder who had previously received an incorrect diagnosis for their  
49 frontotemporal degeneration related symptoms and the amount of time it  
50 took to receive the frontotemporal degeneration disorder diagnosis.

51 2. The yearly report shall be published in a downloadable format on  
52 the department's website and the designated New York state frontotempo-  
53 ral degeneration registry website.

54 § 2. This act shall take effect on the thirtieth day after it shall  
55 have become a law.